tag lymphoma 
Pharmaceutical Technology
MAY 2, 2023
In contrast to ICIs, which are utilised against solid tumours, cell therapies and bispecifics have been transformational in the haematological cancer settings, with approvals across a range of leukaemias and lymphomas. Cost-related unmet needs also scored highly.
European Pharmaceutical Review
DECEMBER 27, 2023
Currently CAR T-cell therapy is approved for three indications: acute lymphoblastic leukaemia (ALL), non-hodgkin lymphoma (NHL), and multiple myeloma (MM) – and the strongest correlation between CAR T-cell efficacy and persistence has been demonstrated in ALL. This is in addition to its considerable price tag. Leukemia & Lymphoma.
Expert insights. Personalized for you.
52 
Let's personalize your content